The Claim
Alirocumab reduces the risk of major adverse cardiovascular events by 65% (OR 0.35, 95% CI: 0.16–0.77) and lowers both cardiovascular and all-cause mortality in high-risk cardiovascular patients compared to placebo, based on available randomized controlled trial data, although the mortality findings are derived from limited event counts and lack confirmation from head-to-head trials.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A drug called alirocumab may help prevent serious heart problems and even lower the chance of dying from heart disease in people at high risk — but we’re still not totally sure about the life-extending effects because the data is limited.
See the scientific wording
Alirocumab reduces the risk of major adverse cardiovascular events (MACE) by 65% (OR 0.35, 95% CI: 0.16–0.77) and lowers both cardiovascular and all-cause mortality in high-risk cardiovascular patients compared to placebo, based on available RCT data, though the mortality findings are based on limited event counts and lack confirmation from head-to-head trials.
What the research says
1 studyThe study looked at Alirocumab and found it cuts the risk of serious heart problems by about 65%, just like the claim says, and also lowers the chance of dying from heart issues or any cause.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.